Neurocrine Biosciences, Inc.

NASDAQ (USD): Neurocrine Biosciences, Inc. (NBIX)

Last Price

135.45

Today's Change

-0.81 (0.59%)

Day's Change

134.14 - 136.05

Trading Volume

399,733

Overview

Market Cap

13 Billion

Shares Outstanding

100 Million

Avg Volume

815,368

Avg Price (50 Days)

137.52

Avg Price (200 Days)

127.27

PE Ratio

36.81

EPS

3.68

Earnings Announcement

30-Jul-2024

Previous Close

136.26

Open

135.54

Day's Range

134.14 - 136.05

Year Range

93.02 - 148.37

Trading Volume

399,733

Price Change Highlight

1 Day Change

-0.59%

5 Day Change

0.19%

1 Month Change

-4.81%

3 Month Change

-2.62%

6 Month Change

12.67%

Ytd Change

2.82%

1 Year Change

39.65%

3 Year Change

37.62%

5 Year Change

57.46%

10 Year Change

803.00%

Max Change

983.60%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment